mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-23. Numbers and descriptions here follow the published literature rather than marketing material.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
=== Names === Mesocarb is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known by the synonym fensidnimine as well as by the brand names Sydnocarb and Synocarb. The drug is additionally known by its developmental code name MLR-1017 (for Parkinson's disease).
Weapon-grade uranium obtained from nuclear weapons is diluted with uranium-238 and reused as fuel for nuclear reactors. Spent nuclear fuel forms radioactive waste, which mostly consists of uranium-238 and poses a significant threat to health and to the environment.
There are many physiological mechanisms that control starting and stopping a meal. The control of food intake is a physiologically complex, motivated behavioral system. Hormones such as cholecystokinin, bombesin, neurotensin, anorectin, calcitonin, enterostatin, leptin and corticotropin-releasing hormone have all been shown to suppress food intake. Eating rapidly leads to obesity and overeating, probably because the feelings of satiety can be slower.
Sources: en.wikipedia.org
== Potential Health benefits == PRP-rich preparations from bovine colostrum have shown possible efficacy against various illnesses including neurodegenerative diseases (such as Alzheimer's), viral infections, and ailments characterized by an overactive immune system, such as allergies, asthma and autoimmune diseases. Some recent research has also indicated possible efficacy in combating obesity.
Atoms were thought to be the smallest possible division of matter until 1899 when J. J. Thomson discovered the electron through his work on cathode rays. A Crookes tube is a sealed glass container in which two electrodes are separated by a vacuum. When a voltage is applied across the electrodes, cathode rays are generated, creating a glowing patch where they strike the glass at the opposite end of the tube. Through experimentation, Thomson discovered that the rays could be deflected by electric fields and magnetic fields, which meant that these rays were not a form of light but were composed of very light charged particles, and their charge was negative. Thomson called these particles "corpuscles". He measured their mass-to-charge ratio to be several orders of magnitude smaller than that of the hydrogen atom, the smallest atom. This ratio was the same regardless of what the electrodes were made of and what the trace gas in the tube was. In contrast to those corpuscles, positive ions created by electrolysis or X-ray radiation had mass-to-charge ratios that varied depending on the material of the electrodes and the type of gas in the reaction chamber, indicating they were different kinds of particles. In 1898, Thomson measured the charge on ions to be roughly 6 × 10−10 electrostatic units (2 × 10−19 Coulombs).
The entire record of UNSCOM until that date had shown a determination on the part of the Iraqi dictatorship to build dummy facilities to deceive inspectors, to refuse to allow scientists to be interviewed without coercion, to conceal chemical and biological deposits, and to search the black market for material that would breach the sanctions. The defection of Saddam Hussein's sons-in-law, the Kamel brothers, had shown that this policy was even more systematic than had even been suspected. Moreover, Iraq did not account for – has in fact never accounted for – a number of the items that it admitted under pressure to possessing after the Kamel defection. We still do not know what happened to this weaponry. This is partly why all Western intelligence agencies, including French and German ones quite uninfluenced by Ahmad Chalabi, believed that Iraq had actual or latent programs for the production of WMD. Would it have been preferable to accept Saddam Hussein's word for it and to allow him the chance to re-equip once more once the sanctions had further decayed?
Sources: en.wikipedia.org
Claude Bosi and his wife Claire opened Hibiscus in Ludlow, Shropshire, in 2000. The location had a 36-seat capacity, and was previously occupied by a three AA Rosette restaurant called the Oaks. Bosi had previously been head chef and won a Michelin star at the Overton Grange restaurant, just outside the town. He had intended to open a restaurant in Warwickshire, but found the premises too expensive and purchased a 25-year lease on the former Oaks property in Ludlow for £40,000. Within a year Hibiscus won its first Michelin star, and at the same time Overton Grange was downgraded before going into receivership. Working under Bosi at Hibiscus was sous chef Glynn Purnell, who left Hibiscus in 2003 to become head chef at Jessica's restaurant in Edgbaston. Hibiscus gained a second star in the 2004 Michelin Guide. In July 2006, Bosi and his wife Claire announced that they were intending to sell Hibiscus and open a new restaurant closer to London, or in the capital itself. Hibiscus closed in Ludlow in April 2007, with Bosi selling the site to fellow chef Alan Murchison for £247,500, but retaining the Hibiscus name for himself. The restaurant was renamed "Le Becasse" (sic), and underwent a £100,000 makeover before being re-opened under head chef Will Holland. In 2014, Murchison's company went into voluntary liquidation after running up debts of almost half a million pounds. Bosi completed the deal in June 2007 for a new site at 29 Maddox Street in London.
Alimentary Pharmacology & Therapeutics is a bimonthly peer-reviewed medical journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems, particularly with relevance to clinical practice. The journal publishes original papers concerned with all aspects of basic and clinical pharmacology, pharmacokinetics, and the therapeutic use of drugs in the alimentary tract including the liver, gall bladder, and pancreas. Its editors are J. M. Rhodes and C. W. Howden.
== History == Phage display was first described by George P. Smith in 1985, when he demonstrated the display of peptides on filamentous phage (long, thin viruses that infect bacteria) by fusing the virus's capsid protein to one peptide out of a collection of peptide sequences. This displayed the different peptides on the outer surfaces of the collection of viral clones, where the screening step of the process isolated the peptides with the highest binding affinity. In 1988, Stephen Parmley and George Smith described biopanning for affinity selection and demonstrated that recursive rounds of selection could enrich for clones present at 1 in a billion or less. In 1990, Jamie Scott and George Smith described creation of large random peptide libraries displayed on filamentous phage. Phage display technology was further developed and improved by groups at the Laboratory of Molecular Biology with Greg Winter and John McCafferty, The Scripps Research Institute with Richard Lerner and Carlos Barbas and the German Cancer Research Center with Frank Breitling and Stefan Dübel for display of proteins such as antibodies for therapeutic protein engineering. Smith and Winter were awarded a half share of the 2018 Nobel Prize in chemistry for their contribution to developing phage display. A patent by George Pieczenik claiming priority from 1985 also describes the generation of peptide libraries.
bumping A phenomenon in which a homogeneous liquid raised to its boiling point becomes superheated and, upon nucleation, rapidly boils to the gas phase, resulting in a violent expulsion of the liquid from the container; in extreme cases, the container itself may shatter. Frequent stirring, the use of an appropriate container, and the use of boiling chips can help prevent bumping.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.